Skip to content

Advertisement

You're viewing the new version of our site. Please leave us feedback.

Learn more

BMC Cancer

Experimental therapeutics and drug development

This section covers all aspects of preclinical investigations on therapeutic agents. It welcomes submissions concerning anti-cancer drug discovery and development, and targeted therapies.

Previous Page Page 1 of 19 Next Page
  1. Content type: Software

    Quantifying the response of cell lines to drugs or other perturbagens is the cornerstone of pre-clinical drug development and pharmacogenomics as well as a means to study factors that contribute to sensitivity...

    Authors: Nicholas A. Clark, Marc Hafner, Michal Kouril, Elizabeth H. Williams, Jeremy L. Muhlich, Marcin Pilarczyk, Mario Niepel, Peter K. Sorger and Mario Medvedovic

    Citation: BMC Cancer 2017 17:698

    Published on:

  2. Content type: Research article

    Neoplastic cells proliferate rapidly and obtain requisite building blocks by reprogramming metabolic pathways that favor growth. Previously, we observed that prostate cancer cells uptake and store lipids in th...

    Authors: Ranjana Mitra, Thuc T. Le, Priyatham Gorjala and Oscar B. Goodman Jr.

    Citation: BMC Cancer 2017 17:631

    Published on:

  3. Content type: Research article

    Programmed cell death 1 (PD1) inhibitors have recently shown promising anti-cancer effects in a number of solid tumor types. A predictive biomarker to this class of drugs has not been clearly identified; howev...

    Authors: Basile Tessier-Cloutier, Steve E. Kalloger, Mohammad Al-Kandari, Katy Milne, Dongxia Gao, Brad H. Nelson, Daniel J. Renouf, Brandon S. Sheffield and David F. Schaeffer

    Citation: BMC Cancer 2017 17:618

    Published on:

  4. Content type: Study protocol

    Metastatic pancreatic cancer has a dismal prognosis, with a mean six-month progression-free survival of approximately 50% and a median survival of about 11 months. Despite intensive research, only slight impro...

    Authors: Jacek Hajda, Monika Lehmann, Ottheinz Krebs, Meinhard Kieser, Karsten Geletneky, Dirk Jäger, Michael Dahm, Bernard Huber, Tilman Schöning, Oliver Sedlaczek, Albrecht Stenzinger, Niels Halama, Volker Daniel, Barbara Leuchs, Assia Angelova, Jean Rommelaere…

    Citation: BMC Cancer 2017 17:576

    Published on:

  5. Content type: Research article

    Mutations of the DNA repair proteins BRCA1/2 are synthetically lethal with the DNA repair enzyme poly(ADP-ribose) polymerase (PARP), which when inhibited, leads to cell death due to the absence of compensatory...

    Authors: Zhor Senhaji Mouhri, Elliot Goodfellow and Bertrand Jean-Claude

    Citation: BMC Cancer 2017 17:540

    Published on:

  6. Content type: Research article

    177Lu-octreotate can be used to treat somatostatin receptor expressing neuroendocrine tumors. It is highly effective in animal models, but clinical studies have so far only demonstrate...

    Authors: Johan Spetz, Britta Langen, Nils Rudqvist, Toshima Z. Parris, Khalil Helou, Ola Nilsson and Eva Forssell-Aronsson

    Citation: BMC Cancer 2017 17:528

    Published on:

  7. Content type: Study protocol

    Non-small cell lung cancer is the most common type of lung cancer. Surgery is proven to be the most effective treatment in early stages, despite its potential impact on quality of life. Pulmonary rehabilitatio...

    Authors: Stefania Fugazzaro, Stefania Costi, Carlotta Mainini, Besa Kopliku, Cristian Rapicetta, Roberto Piro, Roberta Bardelli, Patricia Filipa Sobral Rebelo, Carla Galeone, Giorgio Sgarbi, Filippo Lococo, Massimiliano Paci, Tommaso Ricchetti, Silvio Cavuto, Domenico Franco Merlo and Sara Tenconi

    Citation: BMC Cancer 2017 17:508

    Published on:

  8. Content type: Study protocol

    Metformin is a biguanide oral hypoglycaemic agent commonly used for the treatment of type 2 diabetes mellitus. In addition to its anti-diabetic effect, metformin has also been associated with a reduced risk of...

    Authors: Danielle Crawley, Ashish Chandra, Massimo Loda, Cheryl Gillett, Paul Cathcart, Ben Challacombe, Gary Cook, Declan Cahill, Aida Santa Olalla, Fidelma Cahill, Gincy George, Sarah Rudman and Mieke Van Hemelrijck

    Citation: BMC Cancer 2017 17:494

    Published on:

  9. Content type: Research article

    Cytotoxic efficacy of anticancer drugs has been widely studied with monolayer-cultured cancer cells. However, the efficacy of drugs under two-dimensional (2D) culture condition usually differs from that of thr...

    Authors: Eva Lhuissier, Céline Bazille, Juliette Aury-Landas, Nicolas Girard, Julien Pontin, Martine Boittin, Karim Boumediene and Catherine Baugé

    Citation: BMC Cancer 2017 17:490

    Published on:

  10. Content type: Research article

    As cancer metastasis is the deadliest aspect of cancer, causing 90% of human deaths, evaluating the molecular mechanisms underlying this process is the major interest to those in the drug development field. Bo...

    Authors: Shih-Hsin Tu, Yi-Chen Hsieh, Li-Chi Huang, Chun-Yu Lin, Kai-Wen Hsu, Wen-Shyang Hsieh, Wei-Ming Chi and Chia-Hwa Lee

    Citation: BMC Cancer 2017 17:440

    Published on:

  11. Content type: Research article

    Studies comparing the effect of antiangiogenic agents targeting different angiogenic pathways are sparse. The purpose of this study was to compare the effect of properdistatin and sunitinib treatment in a prec...

    Authors: Jon-Vidar Gaustad, Trude G. Simonsen, Lise Mari K. Andersen and Einar K. Rofstad

    Citation: BMC Cancer 2017 17:411

    Published on:

  12. Content type: Research article

    Doxorubicin (DXR) hydrochloride (HCl) liposome injection is an important part of the treatment armamentarium for a number of cancers. With growing needs for affordable and effective anticancer treatments, the ...

    Authors: Vinod Burade, Subhas Bhowmick, Kuntal Maiti, Rishit Zalawadia, Harry Ruan and Rajamannar Thennati

    Citation: BMC Cancer 2017 17:405

    Published on:

  13. Content type: Research article

    Venetoclax (ABT-199), a first-in-class orally bioavailable BCL-2-selective inhibitor, was recently approved by the FDA for use in patients with 17p-deleted chronic lymphocytic leukemia who have received prior ...

    Authors: Stephen K. Tahir, Morey L. Smith, Paul Hessler, Lisa Roberts Rapp, Kenneth B. Idler, Chang H. Park, Joel D. Leverson and Lloyd T. Lam

    Citation: BMC Cancer 2017 17:399

    Published on:

  14. Content type: Research article

    The prognosis of synovial sarcoma (SS), an aggressive soft tissue sarcoma, remains poor. We previously reported that c-MET or platelet-derived growth factor receptor α (PDGFRα) signalling pathway is related to...

    Authors: Shutaro Yamada, Yoshinori Imura, Takaaki Nakai, Sho Nakai, Naohiro Yasuda, Keiko Kaneko, Hidetatsu Outani, Satoshi Takenaka, Kenichiro Hamada, Akira Myoui, Nobuhito Araki, Takafumi Ueda, Kazuyuki Itoh, Hideki Yoshikawa and Norifumi Naka

    Citation: BMC Cancer 2017 17:334

    Published on:

  15. Content type: Research article

    Mesothelioma is resistant to conventional treatments and is often defective in p53 pathways. We then examined anti-tumor effects of metformin, an agent for type 2 diabetes, and combinatory effects of metformin...

    Authors: Kengo Shimazu, Yuji Tada, Takao Morinaga, Masato Shingyoji, Ikuo Sekine, Hideaki Shimada, Kenzo Hiroshima, Takao Namiki, Koichiro Tatsumi and Masatoshi Tagawa

    Citation: BMC Cancer 2017 17:309

    Published on:

  16. Content type: Research article

    Interstitial lung diseases induced by anticancer agents (ILD-AA) are rare adverse effects of anticancer therapy. However, prognostic biomarkers for ILD-AA have not been identified in patients with advanced lun...

    Authors: Kota Nakamura, Motoyasu Kato, Takehito Shukuya, Keita Mori, Yasuhito Sekimoto, Hiroaki Ihara, Ryota Kanemaru, Ryo Ko, Rina Shibayama, Ken Tajima, Ryo Koyama, Naoko Shimada, Osamu Nagashima, Fumiyuki Takahashi, Shinichi Sasaki and Kazuhisa Takahashi

    Citation: BMC Cancer 2017 17:302

    Published on:

  17. Content type: Research article

    Non-small cell lung cancer (NSCLC) harboring common epidermal growth factor receptor (EGFR) gene mutations (exon 19 deletion or exon 21 L858R) respond to EGFR tyrosine kinase inhibitors (EGFR-TKIs). The second...

    Authors: Masato Chiba, Yosuke Togashi, Eri Bannno, Yoshihisa Kobayashi, Yu Nakamura, Hidetoshi Hayashi, Masato Terashima, Marco A. De Velasco, Kazuko Sakai, Yoshihiko Fujita, Tetsuya Mitsudomi and Kazuto Nishio

    Citation: BMC Cancer 2017 17:281

    Published on:

  18. Content type: Research article

    Metastasis is the leading cause of death in breast cancer patients. CD73, also known as ecto-5′-nucleotidase, plays a critical role in cancer development including metastasis. The existing researches indicate ...

    Authors: Xu Yang, Shimin Pei, Huanan Wang, Yipeng Jin, Fang Yu, Bin Zhou, Hong Zhang, Di Zhang and Degui Lin

    Citation: BMC Cancer 2017 17:255

    Published on:

  19. Content type: Research article

    Central nervous system (CNS) brain metastasis of advanced non-small cell lung cancer (NSCLC) patients confers a worse quality of life and prognosis. The efficacy comparison of two first-generation epidermal gr...

    Authors: Meng-Xia Li, Hao He, Zhi-Hua Ruan, Yu-Xi Zhu, Rong-Qing Li, Xiao He, Bao-Hua Lan, Zhi-Min Zhang, Guo-Dong Liu, Hua-Liang Xiao, Yan Wu, Bo Zhu, Ge Wang and Zhen-Zhou Yang

    Citation: BMC Cancer 2017 17:245

    Published on:

  20. Content type: Research article

    Expression and activity of heparanase, an endoglycosidase that cleaves heparan sulfate (HS) side chains of proteoglycans, is associated with progression and poor prognosis of many cancers which makes it an att...

    Authors: C. P. Baburajeev, Chakrabhavi Dhananjaya Mohan, Shobith Rangappa, Daniel J. Mason, Julian E. Fuchs, Andreas Bender, Uri Barash, Israel Vlodavsky, Basappa and Kanchugarakoppal S. Rangappa

    Citation: BMC Cancer 2017 17:235

    Published on:

Previous Page Page 1 of 19 Next Page